Rhythm Pharmaceuticals develops and commercializes therapeutics for rare genetic diseases of obesity. Its lead product candidate is IMCIVREE, a melanocortin-4 receptor for the treatment of POMC, LEPR deficiency obesity, and Bardet-Biedl and Alström syndrome. The company is also developing setmelanotide for various MC4R disorders. Rhythm Pharmaceuticals was founded in 2008 and is headquartered in Boston, Massachusetts.